B. Riley Wealth Advisors Inc. Has $208,000 Stock Holdings in Humana Inc. (NYSE:HUM)

B. Riley Wealth Advisors Inc. decreased its position in Humana Inc. (NYSE:HUM) by 12.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 712 shares of the insurance provider’s stock after selling 101 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Humana were worth $208,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Pzena Investment Management LLC lifted its position in Humana by 538.7% in the second quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock worth $866,250,000 after purchasing an additional 1,955,375 shares during the period. Marshall Wace LLP lifted its holdings in shares of Humana by 118.9% during the 2nd quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after acquiring an additional 774,085 shares during the period. International Assets Investment Management LLC boosted its position in shares of Humana by 261,025.1% during the 3rd quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock valued at $2,340,660,000 after acquiring an additional 738,701 shares in the last quarter. FMR LLC increased its stake in Humana by 23.4% in the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after acquiring an additional 643,291 shares during the period. Finally, Baupost Group LLC MA acquired a new position in Humana in the second quarter worth about $156,933,000. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

Shares of NYSE HUM opened at $247.10 on Friday. The company has a fifty day moving average price of $273.79 and a 200 day moving average price of $320.62. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $475.00. The firm has a market cap of $29.75 billion, a PE ratio of 21.89, a PEG ratio of 2.15 and a beta of 0.53. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The business had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Research analysts predict that Humana Inc. will post 16.14 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.43%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio is currently 31.36%.

Analyst Ratings Changes

Several research firms have recently weighed in on HUM. Leerink Partners lowered Humana from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $395.00 price objective on shares of Humana in a report on Tuesday, October 1st. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Humana from $349.00 to $250.00 and set a “hold” rating for the company in a research note on Thursday, October 3rd. Morgan Stanley lifted their target price on shares of Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 17th. Finally, Truist Financial cut their price target on Humana from $400.00 to $260.00 and set a “hold” rating on the stock in a research note on Friday, October 11th. Twenty research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $300.50.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.